<DOC>
	<DOCNO>NCT01994265</DOCNO>
	<brief_summary>Cognitive functional decline observe atrial fibrillation ( AF ) patient related thrombotic and/or cardioembolic event . Use warfarin prevention stroke AF patient , despite effective , remain beyond desired level interaction food fluctuation blood level . Because stable anticoagulation state , Dabigatran may offer good protection thrombotic phenomenon , consequently , mitigate process cognitive functional compromise .</brief_summary>
	<brief_title>Cognitive Impairment Related Atrial Fibrillation Prevention Trial</brief_title>
	<detailed_description>This prospective parallel study include two hundred atrial fibrillation patient &gt; 65 year old score CHADS2VASc &gt; 1 . Patients randomize receive Warfarin ( INR 2 3 ) Dabigatran ( 150 mg twice daily ) two year . After one year end study , individual evaluate regard cognitive endpoint follow National Institute Neurological Disorders Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards ( Hachinski et al . Stroke 2006 ; 37:2220-2241 ) . The investigator use 60 minute evaluation protocol complement Montreal Cognitive Assessment ( MoCA ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Atrial fibrillation CHA2DS2VASc Score Atrial Fibrillation Stroke Risk ( CHADS2VASc ) great 1 Heart valve disease Previous Stroke Transient ischemic attack Cognitive impairment severe neurological disorder Major surgery last 30 day Planned elective surgery next three month Intracranial , ocular , spinal , retroperitoneal , articular bleeding without trauma . Gastrointestinal bleeding last 12 month Symptomatic gastric ulcer Hemorrhagic disease Use thrombolytic Uncontrolled hypertension Active cancer Contraindication Warfarin use Reversible cause atrial fibrillation Creatinine clearance &lt; 30 ml/min Active endocarditis Active hepatitis Severe anemia Left ventricle ejection fraction &lt; 35 %</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Efficacy</keyword>
</DOC>